US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
LENZ Therapeutics, Inc. - Common Stock
(NQ:
LENZ
)
3.590
+0.010 (+0.28%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about LENZ Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
September 29, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
September 22, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
September 15, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
September 08, 2026
From
Pomerantz LLP
Via
GlobeNewswire
LENZ Therapeutics (NASDAQ:LENZ) Q1 Report Shows Revenue Beat But Deepening Losses Sink Stock
↗
May 11, 2026
Via
Chartmill
LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q4 Revenue Miss and Wider Loss Following VIZZ Launch
↗
March 24, 2026
Via
Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
September 01, 2026
From
Pomerantz LLP
Via
GlobeNewswire
LENZ Therapeutics (LENZ) Q2 2026 Earnings Call Transcript
↗
August 19, 2026
Prescription growth surged 45% in July after telehealth launch.
Via
The Motley Fool
Topics
Earnings
LENZ Therapeutics Q2 Earnings Call Highlights
↗
August 11, 2026
LENZ Therapeutics (NASDAQ:LENZ) reported second-quarter revenue of $5.5 million as it continued the commercial launch of VIZZ, citing modest quarterly growth and a pickup in prescription activity...
Via
MarketBeat
Topics
Earnings
LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
August 11, 2026
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026
August 04, 2026
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
July 06, 2026
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand
June 24, 2026
Exclusive license and commercialization agreement includes a significant profit share of gross margin from product sales in addition to an upfront license payment to LENZ
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
June 07, 2026
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
Alpha Wave Global Reduces RadNet Stake, According to Recent SEC Filing
↗
June 02, 2026
RadNet runs a large outpatient imaging network and is building DeepHealth, its AI radiology platform. The upside is clearer if advanced imaging growth and digital health expansion can develop without...
Via
The Motley Fool
Topics
Artificial Intelligence
Regulatory Compliance
Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing
↗
May 27, 2026
COPT Defense Properties serves defense and intelligence tenants near secure government hubs. Investors will be closely watching whether that niche can keep supporting growth while much of the office...
Via
The Motley Fool
Topics
Regulatory Compliance
LENZ Therapeutics to Participate in Upcoming Investor Conferences
May 26, 2026
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics Q1 Earnings Call Highlights
↗
May 11, 2026
LENZ Therapeutics (NASDAQ:LENZ) reported first-quarter 2026 results that showed continued prescription growth for its presbyopia eye drop VIZZ, while management acknowledged that new patient adoption...
Via
MarketBeat
Topics
Earnings
Lenz (LENZ) Q1 2026 Earnings Call Transcript
↗
May 11, 2026
Lenz (LENZ) Q1 2026 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 11, 2026
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom
April 20, 2026
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week
↗
March 27, 2026
It failed to meet expectations for its final quarter of 2025.
Via
The Motley Fool
Why Lenz Therapeutics Stock Crashed Today
↗
March 24, 2026
Is it time to throw away your reading glasses? Maybe not just yet.
Via
The Motley Fool
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
March 24, 2026
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings
↗
March 23, 2026
LENZ Therapeutics (NASDAQ:LENZ) to release Q4 earnings on 3/24. Analysts expect loss of 90 cents/share. Stock gained 5% on Monday. Analyst ratings and accuracy rates available on Benzinga.
Via
Benzinga
LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026
March 17, 2026
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia
March 10, 2026
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics to Present at Upcoming Investor Conferences
February 23, 2026
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
January 20, 2026
From
Pomerantz LLP
Via
GlobeNewswire
LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
January 14, 2026
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
